Latest Filings

Issuer Activity

Overview :: McKesson Corporation (N:MCK) [?]
Business Focus: Drug Retailers Share on StockTwits
Recent Price for MCK
USD 228.700 -0.760 (-0.331%)
NYSE Delayed 15 minutes
Feb 27 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
231.140 231.549 31.32 656,954 53,251.54
1-Day Low 52-Week Low Yield Avg. Volume  
228.345 162.900 0.4% NYSE  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for MCK within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:27pm ET February 27th, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Feb 19/15 Feb 19/15 Nagji Bansi Direct Ownership Common Stock Form 3 : Initial Statement of Beneficial Ownership of Securities    
Feb 19/15 Feb 17/15 Nagji Bansi Direct Ownership Employee Stock Option (Right-to-buy) A - Grant, award or other under Rule 16b-3(d) 12,167  
Feb 18/15 Feb 17/15 Spratt Randall N Direct Ownership Employee Stock Option (Right-to-buy) M - Exercise or conversion exempt under rule 16b-3 -44,523  
Feb 18/15 Feb 17/15 Spratt Randall N Direct Ownership Common Stock S - Open market or private sale -44,523 $225.00
Feb 18/15 Feb 17/15 Spratt Randall N Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 44,523 $57.89
Feb 13/15 Feb 12/15 Spratt Randall N Direct Ownership Employee Stock Option (Right-to-buy) M - Exercise or conversion exempt under rule 16b-3 -843  
Feb 13/15 Feb 12/15 Spratt Randall N Direct Ownership Common Stock S - Open market or private sale -843 $225.00
Feb 13/15 Feb 12/15 Spratt Randall N Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 843 $57.89
Feb 13/15 Feb 11/15 Spratt Randall N Direct Ownership Employee Stock Option (Right-to-buy) M - Exercise or conversion exempt under rule 16b-3 -6,634  
Feb 13/15 Feb 11/15 Spratt Randall N Direct Ownership Common Stock S - Open market or private sale -6,634 $225.00
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for MCK within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:27pm ET February 27th, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Feb 19/15 Feb 17/15 Nagji Bansi Direct Ownership Employee Stock Option (Right-to-buy) A - Grant, award or other under Rule 16b-3(d) 12,167  
Feb 19/15 Feb 19/15 Nagji Bansi Direct Ownership Common Stock Form 3 : Initial Statement of Beneficial Ownership of Securities    
Feb 18/15 Feb 17/15 Spratt Randall N Direct Ownership Employee Stock Option (Right-to-buy) M - Exercise or conversion exempt under rule 16b-3 -44,523  
Feb 18/15 Feb 17/15 Spratt Randall N Direct Ownership Common Stock S - Open market or private sale -44,523 $225.00
Feb 18/15 Feb 17/15 Spratt Randall N Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 44,523 $57.89
Feb 13/15 Feb 12/15 Spratt Randall N Direct Ownership Employee Stock Option (Right-to-buy) M - Exercise or conversion exempt under rule 16b-3 -843  
Feb 13/15 Feb 11/15 Spratt Randall N Direct Ownership Employee Stock Option (Right-to-buy) M - Exercise or conversion exempt under rule 16b-3 -6,634  
Feb 13/15 Feb 12/15 Spratt Randall N Direct Ownership Common Stock S - Open market or private sale -843 $225.00
Feb 13/15 Feb 12/15 Spratt Randall N Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 843 $57.89
Feb 13/15 Feb 11/15 Spratt Randall N Direct Ownership Common Stock S - Open market or private sale -6,634 $225.00
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Consumer Non-Cyclicals Industry:  Drug Retailers
 
See Regulatory Filings on SEC
Key People
John Harvey Hammergren
Chairman of the Board, President, Chief Executive Officer
James A. Beer
Chief Financial Officer, Executive Vice President
Randall N. Spratt
Chief Information Officer, Chief Technology Officer, Executive Vice President
Lori A. Schechter
Executive Vice President, Chief Compliance Officer, General Counsel
Jorge L. Figueredo
Executive Vice President - Human Resources
Patrick J. Blake
Executive Vice President, Group President
Paul Coleman Julian
Executive Vice President, Group President
Bansi Nagji
Executive Vice President - Corporate Strategy and Business Development
Brian S. Tyler
Executive Vice President - Corporate Strategy and Business Development
Company Contact
Address: MCKESSON PLAZA, ONE POST ST
SAN FRANCISCO CA 94104
Tel: 1-415-9838391
Website: www.mckesson.com
IR: See website
Business Overview
McKesson Corporation delivers pharmaceuticals, medical supplies and healthcare information technology. The Company operates in two segments. The McKesson Distribution Solutions segment distributes ethical and drugs and equipment and health and beauty care products throughout North America and internationally. This segment provides pharmaceutical solutions for biotech and pharmaceutical manufacturers, and practice management, technology, clinical support and business solutions to oncology and other specialty practices operating in the community setting. The McKesson Technology Solutions segment includes McKesson Health Solutions, which includes the Company's InterQual clinical criteria solution, claims payment solutions and network performance tools. This segment delivers enterprise-wide clinical, patient care, financial, supply chain, strategic management software solutions, as well as connectivity, outsourcing and other services.
Financial Overview
For the nine months ended 31 December 2014, McKesson Corporation revenues increased 36% to $135.82B. Net income before extraordinary items increased 35% to $1.37B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Dividend per share increased from $0.68 to $0.72. Basic Earnings per Share excluding Extraordinary Items increased from $4.45 to $5.94.
Employees: 42,800 as of Mar 31, 2014
Reporting Currency: U.S. Dollars
Enterprise value: $59,059M as of Dec 31, 2014
Annual revenue (TTM): $173,962M as of Dec 31, 2014
EBITDA (TTM): $4,326M as of Dec 31, 2014
Net annual income (TTM): $1,741M as of Dec 31, 2014
Free cash flow (TTM): $3,138M as of Dec 31, 2014
Net Debt Last Fiscal Year: $5,807M as of Dec 31, 2014
Shares outstanding: 232,844,521 as of Jan 31, 2015
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
CVS Health (N:CVS)
Cardinal Health (N:CAH)
Prestige Brands Holdings (N:PBH)